Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 CAR-NK Cells + Pembrolizumab + N-803 in Gastric or Head and Neck Cancer
NCT04847466Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of PD-L1 t-haNK in gastric cancer (GC), gastroesophageal junction cancer, head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Dec 2021; status: completed.
02
Drugs
PD-L1 t-haNK
03
Conditions
gastric cancer (GC)gastroesophageal junction cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04847466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847466.